Form 4: Astera Labs Director Manuel Alba Sells Over 92,000 Shares Under Pre-Planned Trading Program

Astera Labs Director Manuel Alba has reported the sale of 92,991 shares of common stock across multiple transactions on July 2 and 3, 2025, executed under a Rule 10b5-1 trading plan.

Summary

• Manuel Alba, a Director and 10% owner of Astera Labs, Inc. (ALAB), reported the sale of 92,991 shares of common stock.
• The sales occurred on July 2, 2025, and July 3, 2025, and were executed automatically pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2024.
• On July 2, 2025, a total of 62,000 shares were sold at weighted average prices ranging from $88.7099 to $92.3655.
• On July 3, 2025, a total of 30,991 shares were sold at weighted average prices ranging from $89.7354 to $93.14.
• The majority of the shares sold were held indirectly through Casa Alameda 2007, LLC and Alba Trust.
• Following these transactions, Manuel Alba's indirect beneficial ownership includes 418,863 shares via Casa Alameda 2007, LLC, 1,887,757 shares via Alba Trust, and 5,000 shares via spouse, along with 2,351 shares held directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While significant insider sales can sometimes be viewed negatively, the fact that these sales were executed under a pre-planned Rule 10b5-1 program mitigates concerns about opportunistic trading, making the event less impactful on sentiment.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which demonstrates a structured and transparent approach to insider stock disposition, mitigating concerns about opportunistic trading.

Negatives

• The director's significant reduction in indirect shareholdings, totaling 92,991 shares, could be perceived by some investors as a signal of reduced confidence, despite being pre-planned.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market interpretation of insider sales.

Future Outlook

This Form 4 filing reports past transactions and does not provide any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine disclosure of insider trading activity and does not provide broader industry context or trends. It reflects an individual director's pre-planned stock disposition.

Corporate Governance

Related Party Transactions

• The majority of the shares sold were held indirectly through Casa Alameda 2007, LLC, of which the Reporting Person is a manager, and Alba Trust, of which the Reporting Person and his spouse are co-trustees. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The sale of a significant number of shares by a director could lead to market speculation, although the 10b5-1 plan typically lessens negative interpretations. It represents a reduction in insider alignment with shareholder interests through direct equity ownership.

Key Dates

Keywords

Astera Labs, ALAB, Form 4, Insider Trading, Stock Sale, Director, Manuel Alba, 10b5-1 Plan, Beneficial Ownership, Equity Securities